Daewoong Pharmaceutical Co. Ltd. secured an exclusive license to Innovo Therapeutics Inc.’s INV-008, a novel oral 15-hydroxyprostaglandin dehydrogenase inhibitor for inflammatory bowel disease (IBD), through a potential ₩662.5 billion (US$443.6 million) deal.